Market Place
Sourcing Support
Sumitomo And Poxel Announce TWYMEEG® Post-Marketing Study Results In Japan
07 Aug 2024 //
BUSINESSWIRE
DSP-5336 Receives FDA Fast Track Designation For AML Treatment
15 Jul 2024 //
PR NEWSWIRE
Sumitomo CEO weighs layoffs in Japan after sharp sales drop, US job cuts: report
27 Jun 2024 //
FIERCE PHARMA
Sumitomo Presents DSP-5336 Clinical Data At EHA 2024
14 Jun 2024 //
PR NEWSWIRE
Sumitomo & Japan National Institute`s universal influenza vaccine enters trials
22 May 2024 //
ENDPTS
Sumitomo Pharma: FDA Accepts sNDA For Vibegron In OAB/BPH Men
13 May 2024 //
PR NEWSWIRE
Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting
07 May 2024 //
PR NEWSWIRE
Roivant launches $1.5 billion share buyback program
02 Apr 2024 //
PRESS RELEASE
Sumitomo Pharma Announces Availability of ORGOVYX® (relugolix) in Canada
12 Mar 2024 //
PR NEWSWIRE
Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity
11 Dec 2023 //
PR NEWSWIRE
Actor becomes first ‘Gemtesa Go-Getter’ in Sumitomo OAB campaign
29 Nov 2023 //
FIERCE PHARMA
Sumitomo and Actress Holly Robinson Peete Extend Time To Go™ Campaign
21 Nov 2023 //
PR NEWSWIRE
Sumitomo to Present Clinical Data Evaluating TP-3654 and DSP-5336
03 Nov 2023 //
PR NEWSWIRE
EC Approves the Commercialisation of RYEQO® for Endometriosis
02 Nov 2023 //
PR NEWSWIRE
Kyorin and Sumitomo to introduce drug for overactive bladder in Taiwan & other Asian countries
06 Mar 2023 //
PRESS RELEASE
Jazz doubles down on sleep disorders, putting down $50M cash on Sumitomo drug
06 May 2022 //
ENDPTS
Sumitomo Pharma takes license to CRISPR/Cas9 patent portfolio from ERS Genomics
28 Apr 2022 //
BIOSPECTRUMASIA
Sumitomo Dainippon Begins Dosing in Phase 1/2 Study of DSP-5336 in Leukemia
29 Mar 2022 //
PRNEWSWIRE
Sumitomo Dainippon, Sumitovant Biopharma Initiate Phase 1 Study
10 Feb 2022 //
PRESS RELEASE
Sunovion and Otsuka Initiate Phase 3 Development of Non-Racemic Amisulpride
09 Feb 2022 //
BUSINESSWIRE
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2022 [IFRS]
31 Jan 2022 //
PRESS FRELEASE
Takeda to take back Replagal rights
26 Nov 2021 //
THEPHARMALETTER
Sumitomo Dainippon Announces First Patient Dosed in Phase 1 Study of DSP-0390
21 Oct 2021 //
PRNEWSWIRE
Sumitomo Dainippon Pharma inks deal for VR-based DTx with BehaVR
20 Oct 2021 //
MOBIHEALTHNEWS
FDA mistakingly awards priority review to Enzyvant`s regenerative therapy
02 Oct 2021 //
ENDPTS
Otsuka and Sunovion Ink Neuropsychiatric Medicine Deal
01 Oct 2021 //
ENDPTS
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development
30 Sep 2021 //
BUSINESSWIRE
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG
23 Jun 2021 //
BUSINESSWIRE
Roivant`s data spinout merges with rival in $7B deal
09 Jun 2021 //
ENDPTS
Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational
09 Apr 2021 //
PRNEWSWIRE
Japanese drugmaker takes full control of a Roivant biotech
13 Nov 2020 //
BIOPHARMADIVE
Sumitomo Dainippon to Present Data Evaluating Investigational Agent Alvocidib
06 Nov 2020 //
PRNEWSWIRE
Sumitomo begins patient dosing in ph2 study DSP-7888
30 Oct 2020 //
PHARMABIZ
Sumitomo Dainippon Oncology Announces First Patient Dosed in the Dubermatinib
23 Oct 2020 //
PRNEWSWIRE
Sumitomo Chemical and Sumitomo Dainippon Pharma Announce Establishment
08 Oct 2020 //
PRESS RELEASE
Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon
05 Aug 2020 //
GLOBENEWSWIRE
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger
30 Jun 2020 //
PRNEWSWIRE
Latuda Challenged Again over Use Patent Validity in US: Sumitomo Dainippon
23 Jun 2020 //
PHARMA JAPAN
Sunovion ditches once-rejected ADHD, binge eating program
13 May 2020 //
FIERCE BIOTECH
Sumitomo Dainippon Chair Sees No Need for Further Consolidation among Japan
21 Apr 2020 //
PHARMA JAPAN
Sumitomo Dainippon Pharma Announces the Approval of RETHIO®
25 Mar 2020 //
PRESS RELEASE
Astellas alum Robinson takes the helm at Urovant
24 Mar 2020 //
FIERCE BIOTECH
Sumitomo Dainippon, Exscientia begin clinical study of AI based OCD drug
03 Feb 2020 //
BIOSPECTRUMASIA
Sumitomo Dainippon Pharma & Exscientia Joint Development New Drug Candidate
30 Jan 2020 //
PRESS RELEASE
Urovant inks $300M loan agreement with Sumitomo Pharma
01 Jan 2020 //
BIOSPECTRUMASIA
Sumitomo, Roivant close $3 billion deal, forming Sumitovant
01 Jan 2020 //
PHARMAPHORUM
Roivant, Sumitomo alliance to target cystic fibrosis gene therapy
01 Nov 2019 //
BIOPHARMADIVE
BeiGene, Sumitomo-Roivant, Roche-JHL and more
13 Sep 2019 //
FIERCE PHARMA
Roivant lines up $3B upfront in Sumitomo Dainippon deal
06 Sep 2019 //
FIERCEBIOTECH
Sumitomo Dainippon Pharma & Roivant Sciences Enter into a Memorandum
05 Sep 2019 //
PR NEWSWIRE
Sumitomo Dainippon seeks to expand Lonasen use in Japan
22 Jul 2019 //
THE PHARMALETTER
Sumitomo Dainippon confirms takeover talks with Cynata
20 Jul 2019 //
THE PHARMALETTER
Boston Biomedical to discontinue phase 3 CanStem111P study of napabucasin
06 Jul 2019 //
PHARMABIZ
Another effort on pancreatic cancer flops, as Boston Biomedical cans Ph 3 test
02 Jul 2019 //
FIERCE BIOTECH
Poxel and Sumitomo Dainippon Pharma Announce Positive Results for Imeglimin Ph 3
26 Jun 2019 //
BIOSPACE
Poxel & Sumitomo Dainippon Announce Positive Top-Line Results for Imeglimin ph3
09 Apr 2019 //
BUISNESSWIRE
Exscientia Launches New Subsidiary
25 Mar 2019 //
CONTRACTPHARMA
Latuda (lurasidone hydrochloride) : Sumitomo D. Pharma vs. Alkem Laboratories
19 Oct 2018 //
PATENT LITIGATION
Latuda® (lurasidone HCl) : Sumitomo D. Pharma, Sunovion vs. Macleods Pharma
22 Sep 2018 //
PATENT LITIGATION
